@entity4967 and XXXX in serious @entity281 .

@entity1 @entity9102 @entity295 @entity796 @entity137 @entity6 @entity798 @entity281 @entity4967 @entity1778 @entity12088 @entity1729 @entity1290 @entity293 @entity526
In an open, non-comparative study 40 @entity1 with severe, often life-threatening @entity281 , were treated with @entity9102 5.2 g (5 g @entity4967 plus 200 mg @entity798 ) by iv infusion every 6 or 8 h. They were suffering from @entity295 (9), obstructed UTI (8), @entity293 (10), @entity1729 (6), infected burns (4) or @entity12088 (3). Many @entity1 had important aggravating factors such as renal transplantation, peritoneal or haemodialysis, @entity1778 , extensive burns, @entity1290 , tracheostomy and @entity6 . Pathogens included @entity796 (21), @entity526 (7), and other Enterobacteriaceae (6). Twenty-four pathogens (13 @entity796 ) were @entity4967 -resistant. Thirty-six @entity1 were clinically cured including all cases of @entity12088 , @entity281 . Three @entity1 improved and one @entity1 with obstructed @entity293 failed. In 32 @entity1 the pathogen was eradicated, in one @entity1 it persisted and in seven it reappeared. In particular, 11 of 13 @entity1 with @entity281 due to @entity4967 -resistant @entity796 were cured and two improved. There was, however, bacteriological relapse in five. There were no side-effects or evidence of @entity137 in any of the @entity1 . In an in-vitro study a synergistic effect between @entity4967 and @entity798 was noted against Enterobacteriaceae but only a slight synergistic effect against @entity796 . Studies in @entity1 with normal liver and kidney function showed pharmacokinetic compatibility of the two agents. @entity9102 can be recommended for the initial treatment of serious @entity281 .
